Möbus 2003.

Methods	Retrospective uncontrolled study
Participants	44 ovarian cancer patients with clinical recurrence after primary therapy
Interventions	Intravenous monoclonal antibody (oregovomab ‐ CA‐125)
Outcomes	Survival (time from first dose to death/overall survival) Immune response: humoral (Ab2, Ab3, HAMA) Adverse events
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Uncontrolled trial
Allocation concealment (selection bias)	High risk	Uncontrolled trial
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Selective reporting (reporting bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Other bias	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’